Chinese Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (5A) Registry protocol: rationale, design and methodology.

"Declarations Ethics approval and consent to participateAll study participants will provide signed written informed consent at admission before enrollment in the study and data extraction. This study has obtained ethical approval from The Institutional Review Board of Beijing Anzhen Hospital of Capital Medical University and Nanjing Medical University approved this study (first version KL20153256, updated version 2.0, No. 2021-SR-281) and rest of all participating centers, in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This work was supported in part by the National Natural Science Foundation of China (82000305, 82070483), Public Welfare Project of Nanjing Medical University Alliance for Specific Diseases (JZ23349020230306), and Jiangsu Province Capability Improvement Project through Science, Technology and Education (ZDXK202230)."

"Trial registration ClinicalTrials.gov Identifier: NCT04398992 (Initial Release: 05/19/2020)."